Erasca (ERAS) Preferred Stock Liabilities (2020 - 2021)
Erasca (ERAS) reported Preferred Stock Liabilities of $340.8 million for Q2 2021, up 88.23% on a YoY basis from $181.0 million in Q2 2020, and little changed quarter-over-quarter from $340.8 million in Q1 2021.
Erasca (ERAS) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Erasca has reported Preferred Stock Liabilities for 2 years, with the latest figure at $340.8 million in Q2 2021.
- For the quarter ending Q2 2021, Preferred Stock Liabilities rose 88.23% year-over-year to $340.8 million; the trailing twelve-month figure through Jun 2021 stood at $340.8 million (up 88.23% YoY), and the FY2020 full-year result was $221.4 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q2 2021 stood at $340.8 million, roughly flat from $340.8 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $340.8 million in Q1 2021, with the low at $181.0 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Erasca | 4.16 Bn | 3.92 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 340.80 Mn |
| Mar 31, 2021 | 340.80 Mn |
| Dec 31, 2020 | 221.41 Mn |
| Sep 30, 2020 | 191.40 Mn |
| Jun 30, 2020 | 181.05 Mn |